The U.S. Food and Drug Administration said in a court filing on Friday that it agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly’s (LLY) blockbuster weight loss and diabetes drugs and would now allow compounding pharmacies and facilities to keep providing the drugs while it reviews whether there is a shortage of their active ingredient, reported Reuters on Friday. The decision was in response to a lawsuit brought by a compounding industry group, the Outsourcing Facilities Association, and after the FDA’s decision on Friday to reconsider, U.S. District Judge Mark Pittman in Texas put the lawsuit on hold, the report noted. Shares of Hims & Hers (HIMS), which offers compounded weight loss drugs, are up 10% to $20.61 in early Monday trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Unusually active option classes on open October 14th
- WeightWatchers (NASDAQ:WW) Stock Jumps 40% on Plan to Sell Obesity Medications
- HIMS Stock Rises 208% in a Year and Is Ready to Compete with the Big Guns
- Hims & Hers to replace Vector Group in the S&P 600 as of 10/9
- Hims & Hers falls after FDA says Lilly weight loss drug shortage is over